fda glp-1 compounding crackdown news today The announced plans to take action against non-FDA-approved receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the FDA Intensifies Crackdown on GLP-1

That has limited sustained use, especially because these medicines are typically taken over months and often longer

Brought to you by SAMHSA

Chronic intestinal inflammation is the typical feature of IBD

Wegovy (semaglutide) and Qsymia (phentermine/topiramate) represent two distinct pharmacological approaches to weight management, each working through different mechanisms to support weight loss in adults with obesity or overweight with weight-related comorbidities

That is a fundamental shift in how clinicians approach postpartum weight management

GLP-1 is primarily released by specialised cells in your intestines, known as L cells, in response to food intake.When you eat, GLP-1 acts as a powerful messenger, signalling to various parts of your body that its time to process nutrients